DaVita (NYSE:DVA) Insider Sells $3,210,402.00 in Stock

DaVita Inc. (NYSE:DVA) insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

DaVita Stock Performance

Shares of DVA stock opened at $207.65 on Friday. The stock’s 50-day moving average is $182.22 and its two-hundred day moving average is $149.19. The firm has a market cap of $13.33 billion, a price-to-earnings ratio of 19.26, a PEG ratio of 0.68 and a beta of 0.91. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $213.44.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts predict that DaVita Inc. will post 15.07 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and raised their target price for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. Truist Financial increased their price target on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Barclays lifted their price objective on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $199.17.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC grew its position in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the last quarter. Goldman Sachs Group Inc. raised its position in DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after buying an additional 28,739 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of DaVita by 7.0% in the second quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after acquiring an additional 172 shares in the last quarter. Bank of Nova Scotia boosted its holdings in shares of DaVita by 3.8% in the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after acquiring an additional 176 shares in the last quarter. Finally, Natixis increased its stake in shares of DaVita by 80.9% during the second quarter. Natixis now owns 7,297 shares of the company’s stock worth $1,039,000 after acquiring an additional 3,264 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.